144 related articles for article (PubMed ID: 26166038)
1. miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.
Zhang WL; Zhang JH; Wu XZ; Yan T; Lv W
Int J Oncol; 2015 Sep; 47(3):1043-53. PubMed ID: 26166038
[TBL] [Abstract][Full Text] [Related]
2. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
4. MiR-195 inhibits the ubiquitination and degradation of YY1 by Smurf2, and induces EMT and cell permeability of retinal pigment epithelial cells.
Fu SH; Lai MC; Zheng YY; Sun YW; Qiu JJ; Gui F; Zhang Q; Liu F
Cell Death Dis; 2021 Jul; 12(7):708. PubMed ID: 34267179
[TBL] [Abstract][Full Text] [Related]
5. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Hiramoto H; Muramatsu T; Ichikawa D; Tanimoto K; Yasukawa S; Otsuji E; Inazawa J
Sci Rep; 2017 Jun; 7(1):4002. PubMed ID: 28638102
[TBL] [Abstract][Full Text] [Related]
6. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
7. CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.
Cui Y; Song Y; Yan S; Cao M; Huang J; Jia D; Liu Y; Zhang S; Fan W; Cai L; Li C; Xing Y
Aging (Albany NY); 2020 Oct; 12(20):20047-20068. PubMed ID: 33099540
[TBL] [Abstract][Full Text] [Related]
8. TTC3 contributes to TGF-β
Kim JH; Ham S; Lee Y; Suh GY; Lee YS
Cell Death Dis; 2019 Jan; 10(2):92. PubMed ID: 30696809
[TBL] [Abstract][Full Text] [Related]
9. The MRTF-A/B function as oncogenes in pancreatic cancer.
Song Z; Liu Z; Sun J; Sun FL; Li CZ; Sun JZ; Xu LY
Oncol Rep; 2016 Jan; 35(1):127-38. PubMed ID: 26498848
[TBL] [Abstract][Full Text] [Related]
10. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition.
Xiao X; Huang C; Zhao C; Gou X; Senavirathna LK; Hinsdale M; Lloyd P; Liu L
Arch Biochem Biophys; 2015 Jan; 566():49-57. PubMed ID: 25524739
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
12. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Yu S; Wang M; Zhang H; Guo X; Qin R
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
[TBL] [Abstract][Full Text] [Related]
13. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.
Johansson J; Berg T; Kurzejamska E; Pang MF; Tabor V; Jansson M; Roswall P; Pietras K; Sund M; Religa P; Fuxe J
Oncogene; 2013 Dec; 32(50):5614-24. PubMed ID: 23955085
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
15. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3.
Zhu L; Qin H; Li PY; Xu SN; Pang HF; Zhao HZ; Li DM; Zhao Q
J Exp Clin Cancer Res; 2012 Mar; 31(1):29. PubMed ID: 22458379
[TBL] [Abstract][Full Text] [Related]
16. miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Mody HR; Hung SW; Pathak RK; Griffin J; Cruz-Monserrate Z; Govindarajan R
Mol Cancer Res; 2017 Aug; 15(8):1029-1039. PubMed ID: 28373289
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
18. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.
Lou C; Zhang F; Yang M; Zhao J; Zeng W; Fang X; Zhang Y; Zhang C; Liang W
PLoS One; 2012; 7(12):e50956. PubMed ID: 23300530
[TBL] [Abstract][Full Text] [Related]
19. miR-93 promotes TGF-β-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells.
Qu MH; Han C; Srivastava AK; Cui T; Zou N; Gao ZQ; Wang QE
Tumour Biol; 2016 Apr; 37(4):5645-51. PubMed ID: 26581907
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X
Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
